Artivion, Inc. AORT

Full chart Compare
Set alert

Price alert · AORT

All alert types
26.45 USD +2.74 (+11.56%)

At closeNov 4, 2026, 7:58 PM EST

25.93 -0.52 -1.97%

After hours · Nov 4, 7:58 PM ET

24.59 Day range 26.69
19.16 52-week range 48.25
YTD
-42.01%
1 year
-42.20%
Market cap
1.29B
Revenue (ttm)
471.47M
Profit margin
-0.67%
EPS (ttm)
-0.07
Shares out
48.76M
Forward P/E
35.29
YTD return
-42.01%
1-year return
-42.20%
Volume
1.09M
Avg volume
622.88K
Open
24.45
Previous close
23.71
Day's range
24.59 – 26.69
52-week range
19.16 – 48.25
Beta
1.28
Price target
40.91 (+54.7%)
Earnings date
Nov 5, 2026

5D +0.02 (+0.09%)

2222.502323.50TueWedThuFri22.99

Key statistics

Enterprise value
1.49B
PEG ratio
643.75
Price / sales
2.73
Price / book
2.89
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
11.30%
Free cash flow
13.10M
Total cash
77.32M
Total debt
407.97M
Return on equity
-0.73%
Short % of float
9.21%
50-day average
23.71
200-day average
29.19

Financials — quick view

All financials
AORT Revenue — quarterly 125.76M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
AORT Net income — quarterly -13.51M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
AORT EPS — quarterly -0.28
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

AORT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2026Sep 30, 2026-0.06125———
Aug 6, 2026Jun 30, 20260.0025-0.28-0.28-11,300.00%
May 7, 2026Mar 31, 20260.060.03-0.03-50.00%
Feb 12, 2026Dec 31, 20250.140.051-0.09-63.57%
Nov 6, 2025Sep 30, 20250.140.16+0.02+14.29%
Aug 7, 2025Jun 30, 20250.110.0303-0.08-72.45%

Upgrades / downgrades

AORT analyst upgrades and downgrades
DateFirmActionFromTo
Oct 20, 2026Jefferiesinit—Buy
Aug 18, 2026Canaccord GenuitymainBuyBuy
Jul 20, 2026NeedhamreitBuyBuy
Jun 16, 2026Canaccord GenuitymainBuyBuy
May 8, 2026CitizensmainMarket OutperformMarket Outperform
May 8, 2026NeedhammainBuyBuy

About Artivion, Inc.

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
artivion.com

News

Your note

Sign in to keep a note on AORT — it syncs with the Stock Master app.

Insider holders

AORT insider holders
InsiderRelationLatest transactionDateShares held
ACKERMAN THOMAS FDirectorStock Award(Grant)May 17, 2026157,472
BERRY LANCE AChief Operating OfficerSaleAug 13, 2026210,112
BEVEVINO DANIEL JDirectorStock Award(Grant)May 17, 2026157,637
BULLOCK JAMES WDirectorStock Award(Grant)May 17, 202676,223
BURBANK JEFFREY HDirectorStock Award(Grant)May 17, 202661,372
DAVIS JOHN EOfficerSaleMar 2, 2026230,794

Institution ownership

AORT institution ownership
Holder% heldSharesValueReported
Blackrock Inc.13.69%6,674,017176.26MJun 29, 2026
Nomura Asset Management International Inc6.53%3,184,97484.12MJun 29, 2026
Morgan Stanley5.25%2,557,96167.56MJun 29, 2026
Juniper Investment Company, LLC4.14%2,019,88553.35MJun 29, 2026
Vanguard Capital Management LLC4.11%2,004,61952.94MJun 29, 2026
FMR, LLC4.03%1,963,47151.86MJun 29, 2026

Fund ownership

AORT fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF5.95%2,901,33976.62MSep 29, 2026
Delaware Group Equity Funds V-Nomura Small Cap Core Fund3.89%1,898,80950.15MAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.00%1,463,34038.65MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.42%1,180,71731.18MSep 29, 2026
Conestoga Funds-Conestoga Small Cap Fund1.97%962,62025.42MJun 29, 2026
Fidelity Securities Fund-Fidelity Small Cap Value Fund1.94%947,11125.01MAug 30, 2026